2 November 2020 - Novartis Pharmaceuticals Canada is pleased to announce that statistically significant overall survival results for Kisqali (ribociclib succinate) in combination therapy have now been approved within the Kisqali Product Monograph.
The pivotal Phase 3 MONALEESA-7 trial evaluated Kisqali with endocrine therapy (goserelin plus either an aromatase inhibitor or tamoxifen) as initial treatment compared to placebo plus endocrine therapy, in pre- and peri-menopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative advanced or metastatic breast cancer.